NCT05434689 2026-04-15
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT06179888 2026-04-13
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06465316 2026-04-13
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT05583617 2026-04-03
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06896916 2026-03-30
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT06215118 2026-03-27
MagnetisMM-30
Pfizer
Phase 1 Recruiting
NCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting
NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting